{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:31Z","timestamp":1789746211987,"version":"4.0.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T00:00:00Z","timestamp":1654387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Nivolumab, the monoclonal antibody inhibitor of programmed cell death protein 1, enhances the T-cell response, including anti-tumour responses, by blocking the attachment of programmed death-ligand 1 and programmed death-ligand 2 ligands to the programmed cell death protein 1 receptor, which in turn leads to a reduction in tumour growth. Nivolumab has been approved in relapsed or refractory classic Hodgkin's lymphoma after autologous transplantation of haematopoietic stem cell and treatment with brentuximab as monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We herewith report a case of 65-year-old woman who developed an interstitial pneumonitis and a global cardiac hypokinesis following a treatment with Nivolumab for a refractory Hodgkin's Lymphoma. Nivolumab was administered as the fifth line of therapy. Some concomitant patient treatments include drug with known autoimmune toxicities. Although the patient had a persistent complete remission following the sixth infusion, it was discontinued as she developed dyspnea of NYHA stage IV and orthopnea. The chest tomography revealed a bilateral micronodular pattern of organizing pneumonia with bilateral pleural effusion. The forced expiratory volume was decreased to 50%. In parallel her transthoracic echocardiography revealed a global hypokinesis with a left ventricular ejection fraction of 20%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient was treated with empiric antibiotics although the microbial assessments were negative. She was also treated with beta-blocker and angiotensin-converting enzyme inhibitors. The cardiac magnetic resonance imaging performed after 4 months confirmed the hypokinetic cardiopathy with an ejection fraction of 48%. The patient had a significant clinical improvement. The tomography emission positron scan conducted 8 months after interruption of Nivolumab showed complete remission with some moderate activation of residual lesion basal posterior lobe of left lung field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Early and effective diagnosis of immune-related adverse events through the search for predictive biomarkers like drug factors and individual risk factors will allow targeted surveillance leading to a better tolerance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221105572","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T01:11:11Z","timestamp":1654477871000},"page":"479-483","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma"],"prefix":"10.1177","volume":"29","author":[{"given":"Laurence","family":"Bonhomme-Faivre","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Paul Brousse University Hospital, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Troyes General Hospital, Troyes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-6961","authenticated-orcid":false,"given":"Srimanta C","family":"Misra","sequence":"additional","affiliation":[{"name":"Department of Hematology, Troyes General Hospital, Troyes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,5]]},"reference":[{"key":"bibr1-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.03.003"},{"key":"bibr2-10781552221105572","first-page":"1","volume":"360","author":"Baxi S","year":"2018","journal-title":"Br Med J"},{"key":"bibr3-10781552221105572","doi-asserted-by":"publisher","DOI":"10.5414\/CP202110"},{"key":"bibr4-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1659"},{"key":"bibr5-10781552221105572","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1157\/13083574","volume":"126","author":"Lopez-Marina V","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"bibr6-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319"},{"key":"bibr8-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247"},{"key":"bibr9-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1038\/nm955"},{"key":"bibr10-10781552221105572","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"Izzedine H","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"bibr11-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0848-y"},{"key":"bibr12-10781552221105572","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4047"},{"key":"bibr13-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391"},{"key":"bibr14-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.274"},{"key":"bibr15-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795"},{"key":"bibr16-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18742-9"},{"key":"bibr17-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.06.012"},{"key":"bibr18-10781552221105572","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa081"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221105572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221105572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221105572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:11Z","timestamp":1777688831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221105572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10781552221105572"],"URL":"https:\/\/doi.org\/10.1177\/10781552221105572","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,5]]}}}